title: Talc pleurodesis in pleuropulmonary diseases treatment.
abstract: OBJECTIVE
  To determine the efficiency and safety of talc pleurodesis in treating the malignant pleural effusion and recurrent spontaneous pneumothorax.
  
  
  METHODS
  The study included 54 patients with malignant pleural effusion and recurrent spontaneous pneumothorax, who underwent talc pleurodesis using the "talc slurry" method of pleural talc obliteration.
  
  
  RESULTS
  Pleurodesis was successful in 52 (96%) patients. The average duration of thoracic drainage was 4.4 days. Procedure complications included higher body temperature, pneumonia and pleural effusion separation. All of the patients had satisfying radiological findings at the point of discharge and three months later. There was no death outcome related to the procedure of pleurodesis itself.
  
  
  CONCLUSIONS
  Our study has proved the efficiency and simplicity of talc pleurodesis in treating symptomatic malignant pleural effusions and cases with recurrent spontaneous pneumothorax.Appropriate patient selection and compliance with surgical principles during the procedure make this method safe, efficient and successful in treating pleuropulmonal diseases. Large particle talc should be used for pleurodesis because of the minimum risk of complications.
authors.affiliation: 1Department of Thoracic Surgery,2Department of General Surgery,3Clinic for Lung Diseases and Tuberculosis; University Clinical Centre Tuzla, 4Department of Histology, School of Medicine, University of Tuzla,5Institute for Pathology, University Clinical CentreTuzla,6Department ofpPhysiology,School of Medicine, University of Tuzla,7Clinic of Internal Medicine, University Clinical Centre Tuzla; Tuzla, Bosnia and Herzegovina.
authors.forename: Nusret
authors.initials: N
authors.lastname: Ramić
authors.forename: Goran
authors.initials: G
authors.lastname: Krdžalić
authors.forename: Nermin
authors.initials: N
authors.lastname: Mušanović
authors.forename: Ferid
authors.initials: F
authors.lastname: Konjić
authors.forename: Sefika
authors.initials: S
authors.lastname: Umihanić
authors.forename: Suada
authors.initials: S
authors.lastname: Ramić
authors.forename: Jasminka
authors.initials: J
authors.lastname: Mustedanagić-Mujanović
authors.forename: Farid
authors.initials: F
authors.lastname: Ljuca
authors.forename: Enver
authors.initials: E
authors.lastname: Zerem
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010996:Pleural Effusion / Q000473:pathology / Q000628:therapy*; D016066:Pleural Effusion, Malignant / Q000473:pathology / Q000628:therapy*; D018700:Pleurodesis / Q000009:adverse effects / Q000379:methods*; D011030:Pneumothorax / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000008:administration & dosage* / Q000627:therapeutic use*; D013627:Talc / Q000008:administration & dosage*
chemical_list: D012597:Sclerosing Solutions; D013627:Talc